At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
Cisplatin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Cisplatin + AZD1775 in Metastatic Triple-negative Breast Cancer and Evaluation of pCDC2 as a Biomarker of Target Response
In Brief
A Phase 2 clinical trial evaluating Cisplatin and AZD1775 for Triple-negative Metastatic Breast Cancer. Completed, enrolled 34 participants across 1 site.
Detailed Summary
This research study is studying a combination of drugs as a possible treatment for triple-negative breast cancer that has spread to other areas of the body. The names of the study interventions involved in this study are: * Cisplatin * AZD1775
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTriple-negative Metastatic Breast Cancer
CountriesUnited States
CollaboratorsAstraZeneca
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 2017
Enrollment StartJan 2017
Primary CompletionMay 2019
Study CompletionNov 2020
TodayJul 2026
First PostedJan 6, 2017
Enrollment StartJan 18, 2017
Primary CompletionMay 7, 2019
Study CompletionNov 30, 2020
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 9.5 years ago
Interventions
Cisplatindrug
chemotherapy
AZD1775drug
Wee1 tyrosine kinase inhibitor